

AMENDMENT TO THE CLAIMS

Please cancel Claims 1-8 and 24 without prejudice and amend claims 26 and 35 as set forth below. A complete listing of the claims in a revised format now permitted by the USPTO (revision to 37 CFR 1.121) is set forth below.

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Cancelled)

26. (Currently amended) A method of treating a human patient for cancer that can be treated by increasing the activity of one or more proteins of the p53 family in cells affected by said cancer, comprising the steps of:

(a) administering to said patient an effective amount of an organic non-peptide compound that binds, in said cells, to one or more domains of one or more of the patient's proteins of a human protein of the p53 family, and stabilizes a functional conformation of said proteins under physiological conditions, ~~and stabilizes a functional conformation of said protein~~, and

(b) permitting said stabilized protein to interact with one or more macromolecules that participate in a wild-type activity of said protein.

-
27. (Previously added) The method of claim 26 wherein said protein is selected from the group consisting of p53, p63 and p73.
28. (Previously added) The method of claim 26 wherein said protein is p53.
29. (Previously added) The method of claim 26 wherein said organic non-peptide compound binds to the DNA binding domain, residues 94-312, of human p53 protein.
30. (Previously added) The method of claim 26 wherein the protein of the p53 family targeted by said organic non-peptide compound is wild type.
31. (Previously added) The method of claim 26 wherein the protein of the p53 family targeted by said organic non-peptide compound is a mutant encoded by an allelic variant.
32. (Previously added) The method of claim 26, wherein the DNA binding domain of said protein comprises a missense mutation at an amino acid position selected from the group consisting of residues 143, 173, 175, 241, and 249 of p53.
33. (Previously added) The method of claim 26 wherein steps (a) and (b) are performed sequentially.
34. (Previously added) The method of claim 26 wherein steps (a) and (b) are performed simultaneously.

35. (Currently amended) The method of claim 26 wherein said cancer ~~disease~~ state is associated with possession of a mutant protein of the p53 family having one or more diminished wild type activities, comprising the steps of:

(a) administering to said patient an effective amount of an organic non-peptide compound that binds to one or more domains in said mutant protein under physiological conditions, and stabilizes a functional conformation of said protein, and

(b) permitting said stabilized protein to interact with one or macromolecules that participate in said wild type activity.

2
CSM